Literature DB >> 11106562

Production of experimental malignant pleural effusions is dependent on invasion of the pleura and expression of vascular endothelial growth factor/vascular permeability factor by human lung cancer cells.

S Yano1, H Shinohara, R S Herbst, H Kuniyasu, C D Bucana, L M Ellis, I J Fidler.   

Abstract

We determined the molecular mechanisms that regulate the pathogenesis of malignant pleural effusion (PE) associated with advanced stage of human, non-small-cell lung cancer. Intravenous injection of human PC14 and PC14PE6 (adenocarcinoma) or H226 (squamous cell carcinoma) cells into nude mice yielded numerous lung lesions. PC14 and PC14PE6 lung lesions invaded the pleura and produced PE containing a high level of vascular endothelial growth factor (VEGF)-localized vascular hyperpermeability. Lung lesions produced by H226 cells were confined to the lung parenchyma with no PE. The level of expression of VEGF mRNA and protein by the cell lines directly correlated with extent of PE formation. Transfection of PC14PE6 cells with antisense VEGF165 gene did not inhibit invasion into the pleural space but reduced PE formation. H226 cells transfected with either sense VEGF 165 or sense VEGF 121 genes induced localized vascular hyperpermeability and produced PE only after direct implantation into the thoracic cavity. The production of PE was thus associated with the ability of tumor cells to invade the pleura, a property associated with expression of high levels of urokinase-type plasminogen activator and low levels of TIMP-2. Collectively, the data demonstrate that the production of malignant PE requires tumor cells to invade the pleura and express high levels of VEGF/VPF.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11106562      PMCID: PMC1885766          DOI: 10.1016/S0002-9440(10)64828-6

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  40 in total

1.  Density-dependent induction of 92-kd type IV collagenase activity in cultures of A431 human epidermoid carcinoma cells.

Authors:  B Xie; C D Bucana; I J Fidler
Journal:  Am J Pathol       Date:  1994-05       Impact factor: 4.307

2.  Invasion of connective tissue by human carcinoma cell lines: requirement for urokinase, urokinase receptor, and interstitial collagenase.

Authors:  L Ossowski
Journal:  Cancer Res       Date:  1992-12-15       Impact factor: 12.701

3.  Expression of vascular permeability factor/vascular endothelial growth factor by melanoma cells increases tumor growth, angiogenesis, and experimental metastasis.

Authors:  K P Claffey; L F Brown; L F del Aguila; K Tognazzi; K T Yeo; E J Manseau; H F Dvorak
Journal:  Cancer Res       Date:  1996-01-01       Impact factor: 12.701

4.  Pleural effusion in lung cancer.

Authors:  S A Sahn
Journal:  Clin Chest Med       Date:  1993-03       Impact factor: 2.878

5.  Pathogenesis of ascites tumor growth: vascular permeability factor, vascular hyperpermeability, and ascites fluid accumulation.

Authors:  J A Nagy; E M Masse; K T Herzberg; M S Meyers; K T Yeo; T K Yeo; T M Sioussat; H F Dvorak
Journal:  Cancer Res       Date:  1995-01-15       Impact factor: 12.701

6.  Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele.

Authors:  P Carmeliet; V Ferreira; G Breier; S Pollefeyt; L Kieckens; M Gertsenstein; M Fahrig; A Vandenhoeck; K Harpal; C Eberhardt; C Declercq; J Pawling; L Moons; D Collen; W Risau; A Nagy
Journal:  Nature       Date:  1996-04-04       Impact factor: 49.962

7.  A novel vascular endothelial growth factor, VEGF-C, is a ligand for the Flt4 (VEGFR-3) and KDR (VEGFR-2) receptor tyrosine kinases.

Authors:  V Joukov; K Pajusola; A Kaipainen; D Chilov; I Lahtinen; E Kukk; O Saksela; N Kalkkinen; K Alitalo
Journal:  EMBO J       Date:  1996-01-15       Impact factor: 11.598

Review 8.  Management of malignant pleural effusions.

Authors:  J C Ruckdeschel
Journal:  Semin Oncol       Date:  1995-04       Impact factor: 4.929

9.  Increased microvascular permeability and endothelial fenestration induced by vascular endothelial growth factor.

Authors:  W G Roberts; G E Palade
Journal:  J Cell Sci       Date:  1995-06       Impact factor: 5.285

View more
  45 in total

1.  Potential role of AQP1 and VEGF in the development of malignant pleural effusion in mice.

Authors:  Jing Xuan Zhang; C M Xie; Z W Zhu; H Y Huang; Z L Zeng
Journal:  Med Oncol       Date:  2011-04-26       Impact factor: 3.064

Review 2.  Current status and perspective of angiogenesis and antivascular therapeutic strategy: non-small cell lung cancer.

Authors:  Seiji Yano; Yuka Matsumori; Kenji Ikuta; Hirokazu Ogino; Tamir Doljinsuren; Saburo Sone
Journal:  Int J Clin Oncol       Date:  2006-04       Impact factor: 3.402

Review 3.  Switching off malignant pleural effusion formation-fantasy or future?

Authors:  Magda Spella; Anastasios D Giannou; Georgios T Stathopoulos
Journal:  J Thorac Dis       Date:  2015-06       Impact factor: 2.895

4.  SRC tyrosine kinase inhibitor, m475271, suppresses subcutaneous growth and production of lung metastasis via inhibition of proliferation, invasion, and vascularization of human lung adenocarcinoma cells.

Authors:  Rui Zheng; Seiji Yano; Yuka Matsumori; Emiko Nakataki; Hiroaki Muguruma; Masanori Yoshizumi; Saburo Sone
Journal:  Clin Exp Metastasis       Date:  2005       Impact factor: 5.150

5.  Expression of vascular endothelial growth factor and its role in oncogenesis of human gastric carcinoma.

Authors:  D H Liu; X Y Zhang; D M Fan; Y X Huang; J S Zhang; W Q Huang; Y Q Zhang; Q S Huang; W Y Ma; Y B Chai; M Jin
Journal:  World J Gastroenterol       Date:  2001-08       Impact factor: 5.742

Review 6.  Pleural involvement in lung cancer.

Authors:  Theodora Agalioti; Anastasios D Giannou; Georgios T Stathopoulos
Journal:  J Thorac Dis       Date:  2015-06       Impact factor: 2.895

7.  Malignant pleural effusion: further translational research is crucial.

Authors:  Yasuhiko Nishioka
Journal:  Transl Lung Cancer Res       Date:  2012-09

8.  Surfactant protein A suppresses lung cancer progression by regulating the polarization of tumor-associated macrophages.

Authors:  Atsushi Mitsuhashi; Hisatsugu Goto; Takuya Kuramoto; Sho Tabata; Sawaka Yukishige; Shinji Abe; Masaki Hanibuchi; Soji Kakiuchi; Atsuro Saijo; Yoshinori Aono; Hisanori Uehara; Seiji Yano; Julie G Ledford; Saburo Sone; Yasuhiko Nishioka
Journal:  Am J Pathol       Date:  2013-03-14       Impact factor: 4.307

9.  Therapeutic effects of recombinant human endostatin adenovirus in a mouse model of malignant pleural effusion.

Authors:  Fang Fang; Ping Chen; Xin Wu; Li Yang; Xun Yang; Zhen-Xiang Xi; Bin-Wen Zhou; Xi-Kun Zhou; Zhi-Yong Qian; Bo Xiao; Yu-Quan Wei
Journal:  J Cancer Res Clin Oncol       Date:  2009-02-15       Impact factor: 4.553

10.  Specific effects of bortezomib against experimental malignant pleural effusion: a preclinical study.

Authors:  Ioannis Psallidas; Sophia P Karabela; Charalampos Moschos; Taylor P Sherrill; Androniki Kollintza; Sophia Magkouta; Panagiota Theodoropoulou; Charis Roussos; Timothy S Blackwell; Ioannis Kalomenidis; Georgios T Stathopoulos
Journal:  Mol Cancer       Date:  2010-03-10       Impact factor: 27.401

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.